Changing the Properties of Multipotent Mesenchymal Stromal Cells by IFNγ Administration


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

We studied changes in the population of human multipotent mesenchymal stromal cells activated by IFNγ. The cells were cultured under standard conditions; IFNγ was added in various concentrations for 4 h or over 2 passages. It was shown that the total cell production significantly decreased after long-term culturing with IFNγ, but 4-h exposure did not affect this parameter. After 4-h culturing, the expression levels of IDO1, CSF1, and IL-6 increased by 300, 7, and 2.4 times, respectively, and this increase persisted 1 and 2 days after removal of IFNγ from the culture medium. The expression of class I and II MHC (HLA) on cell surface practically did not change immediately after exposure to IFNγ, but during further culturing, HLA-ABC (MHC I) and HLA-DR (MHC II) expression significantly increased, which abolished the immune privilege in these cells, the property allowing clinical use of allogenic multipotent mesenchymal stromal cells. Multipotent mesenchymal stromal cells can suppress proliferation of lymphocytes. The degree of this suppression depends on individual properties of multipotent mesenchymal stromal cell donor. Treatment with IFNγ did not significantly affect the intensity of inhibition of lymphocyte proliferation by these cells.

About the authors

N. A. Petinati

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow

N. M. Kapranov

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow

A. E. Bigil’deev

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow

M. D. Popova

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow

Yu. O. Davydova

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow

I. V. Gal’tseva

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow

N. I. Drize

Hematology Research Center, Ministry of Health Care of the Russian Federation

Author for correspondence.
Email: ndrize@yandex.ru
Russian Federation, Moscow

L. A. Kuz’mina

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow

E. N. Parovichnikova

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow

V. G. Savchenko

Hematology Research Center, Ministry of Health Care of the Russian Federation

Email: ndrize@yandex.ru
Russian Federation, Moscow


Copyright (c) 2017 Springer Science+Business Media, LLC

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies